<DOC>
	<DOCNO>NCT02484729</DOCNO>
	<brief_summary>This study randomize , single-blind , placebo-controlled first-in-human study healthy male subject assess safety , tolerability pharmacokinetics single ascend dos AZD9977 . In Part B study regional absorption AZD9977 along gastro-intestinal tract investigate use IntelliCap® system non-randomized , open-label , fixed-sequence design . The study perform single study centre .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability Pharmacokinetics AZD9977 After Single Ascending Doses Healthy Males</brief_title>
	<detailed_description>This study randomize , single-blind , placebo-controlled first-in-human study healthy male subject assess safety , tolerability pharmacokinetics single ascend dos AZD9977 . In Part B study regional absorption AZD9977 along gastro-intestinal tract investigate use IntelliCap® system non-randomized , open-label , fixed-sequence design oral solution reference . The study perform single study centre .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>1 . Provision sign date write informed consent prior study specific procedure . 2 . Healthy male subject age 18 50 year suitable vein cannulation repeat venipuncture . 3 . Male subject comply restriction sexual activity provide . 4 . Have body mass index ( BMI ) 18 30 kg/m2 inclusive weigh least 50 kg 100 kg inclusive . 5 . Optional : Provision sign date write informed consent genetic research . If subject decline participate genetic component study , penalty loss benefit subject . The subject exclude aspect study describe protocol . 6 . Able understand , read speak English language . 1 . History clinically significant disease disorder , opinion investigator , may either put potential subject risk participation study , influence result potential subject 's ability participate study . 2 . History presence GI , hepatic renal disease , condition know interfere absorption , distribution , metabolism , excretion drug . 3 . Any clinically significant illness , medical/surgical procedure , trauma within 4 week dose Part A first dose AZD9977 Part B . 4 . Any clinically significant abnormality hematology , clinical chemistry urinalysis result , judged investigator . 5 . Any positive result screen serum hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody , human immunodeficiency virus ( HIV ) antibody . 6 . Abnormal finding vital sign , 10 minute rest supine position , define follow : Systolic blood pressure ( SBP ) &lt; 90 mmHg ≥ 140 mmHg Diastolic blood pressure ( DBP ) &lt; 50 mmHg ≥ 90 mmHg Pulse &lt; 45 &gt; 90 bpm 7 . Any clinically important abnormality rhythm , conduction morphology electrocardiogram ( ECG ) screen predose , consider investigator . 8 . Prolonged QTcF &gt; 450 ms family history long QT syndrome . 9 . PR ( PQ ) interval shorten &lt; 120 ms. PR &gt; 110 m &lt; 120 m acceptable evidence ventricular preexcitation . 10 . PR ( PQ ) interval prolongation &gt; 240ms ; intermittent second third degree atrioventricular ( AV ) block , AV dissociation . Wenckebach block asleep exclusive . 11 . Persistent intermittent complete bundle branch block ( BBB ) , incomplete bundle branch block ( IBBB ) , intraventricular conduction delay ( IVCD ) QRS &gt; 110 ms. QRS &gt; 110 m &lt; 115 m acceptable evidence ventricular hypertrophy preexcitation . 12 . Serum potassium high 5.0 mmol/L screen admission study center ( Day 1 ) . 13 . Known suspected history drug abuse judge investigator . 14 . Current smoker smoke used nicotine product within previous 3 month . 15 . History alcohol abuse excessive intake alcohol judge investigator . 16 . Positive screen drug abuse , alcohol cotinine screen admission study center . 17 . History severe allergy/hypersensitivity ongoing clinically important allergy/hypersensitivity , judge investigator history hypersensitivity drug similar chemical structure class AZD9977 . 18 . Excessive intake caffeine contain drink food ( e.g. , coffee , tea chocolate ) judge investigator . 19 . Use drug enzyme induce property St John 's Wort within 3 week prior dose Part A first dose AZD9977 Part B . 20 . Use prescribed nonprescribed medication include antacid , analgesic ( paracetamol/acetaminophen ) , herbal remedy , megadose vitamin ( intake 20 600 time recommended daily dose ) mineral 2 week prior dose Part A first dose AZD9977 Part B , long medication long halflife . 21 . Plasma donation within one month screen blood donation/blood loss &gt; 500 mL 3 month prior screen . 22 . Has receive another new chemical entity ( define compound approve marketing ) within 3 month dose Part A first dose AZD9977 Part B study . The period exclusion begin 3 month final dose one month last visit whichever long . Note : Subjects consent screen , randomize study previous phase I study , exclude . 23 . Involvement AstraZeneca study site employee close relative . 24 . Judgment investigator subject participate study ongoing recent ( i.e. , screen period ) minor medical complaint may interfere interpretation study data consider unlikely comply study procedure , restriction requirement . 25 . Subjects vegans medical dietary restriction ( vegetarian may include study ) . 26 . Subjects communicate reliably investigator . 27 . Vulnerable subject , e.g. , keep detention , protect adult guardianship , trusteeship , committed institution governmental juridical order . In addition , follow regarded criterion exclusion genetic research : 28 . Previous bone marrow transplant . 29 . Nonleukocyte deplete whole blood transfusion within 120 day date genetic sample collection . Criteria applicable Part B : 30 . Subjects pacemaker implant electromedical device . 31 . Subjects swallow disorder . 32 . Subjects preplanned MRI examination . 33 . Subjects willing abdominal Xray perform IntelliCap® capsule retrieve within one week ingestion .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>AZD9977</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>First-in-human</keyword>
	<keyword>Single Ascending Dose</keyword>
	<keyword>Regional absorption</keyword>
	<keyword>Healthy male subject</keyword>
</DOC>